Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

140.31
Delayed Data
As of Nov 17
 0.00 / 0.00%
Today’s Change
95.08
Today|||52-Week Range
149.31
+38.09%
Year-to-Date
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
Nov 17 / Zacks.com - Paid Partner Content
Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss
Nov 10 / Zacks.com - Paid Partner Content
Alnylam Starts Rolling NDA Submission for RNAi Candidate
Nov 17 / Zacks.com - Paid Partner Content
Valeant (VRX) Earnings and Revenues Beat in Q3, Stock Up
Nov 09 / Zacks.com - Paid Partner Content
Valeant (VRX) Announces Pricing of Senior Secured Notes
Nov 15 / Zacks.com - Paid Partner Content
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
Nov 09 / Zacks.com - Paid Partner Content
Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee
Nov 15 / Zacks.com - Paid Partner Content
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
Nov 09 / Zacks.com - Paid Partner Content
Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin
Nov 14 / Zacks.com - Paid Partner Content
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
Nov 09 / Zacks.com - Paid Partner Content
Shire Gets Positive CHMP Opinion for Hemophilia A Drug
Nov 14 / Zacks.com - Paid Partner Content
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3
Nov 09 / Zacks.com - Paid Partner Content
Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA
Nov 14 / Zacks.com - Paid Partner Content
Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3
Nov 08 / Zacks.com - Paid Partner Content
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis
Nov 14 / Zacks.com - Paid Partner Content
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
Nov 08 / Zacks.com - Paid Partner Content
Vertex Gets CHMP Recommendation for Orkambi Label Expansion
Nov 13 / Zacks.com - Paid Partner Content
Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines
Nov 08 / Zacks.com - Paid Partner Content
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study
Nov 13 / Zacks.com - Paid Partner Content
Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates
Nov 08 / Zacks.com - Paid Partner Content
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion
Nov 13 / Zacks.com - Paid Partner Content
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat
Nov 08 / Zacks.com - Paid Partner Content
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
Nov 13 / Zacks.com - Paid Partner Content
Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus
Nov 08 / Zacks.com - Paid Partner Content
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak
Nov 10 / Zacks.com - Paid Partner Content
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND
Nov 08 / Zacks.com - Paid Partner Content
BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates
Nov 10 / Zacks.com - Paid Partner Content
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss
Nov 07 / Zacks.com - Paid Partner Content
Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised
Nov 10 / Zacks.com - Paid Partner Content
What's in Store for Ligand (LGND) This Earnings Season?
Nov 06 / Zacks.com - Paid Partner Content
Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss
Nov 10 / Zacks.com - Paid Partner Content
ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up
Nov 06 / Zacks.com - Paid Partner Content